Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial


Matthews D. R., Paldanius P. M., Proot P., Chiang Y., Stumvoll M., Del Prato S.

LANCET, vol.394, no.10208, pp.1519-1529, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 394 Issue: 10208
  • Publication Date: 2019
  • Doi Number: 10.1016/s0140-6736(19)32131-2
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1519-1529
  • Istanbul University Affiliated: Yes

Abstract

Background Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy has been suggested to offer more opportunities than a traditional stepwise approach, its validity remains to be determined.